KALPANA: Advanced Spectroscopic Signal Processing Platform for Improved Accuracy to Aid in Early Diagnosis of Brain Disorders in Clinical Setting.

Magnetic resonance spectroscopy (MRS) plays a substantial role in the non-invasive detection of brain neurochemicals, antioxidants, and neurotransmitters. Quantitative monitoring of these neurochemicals and neurotransmitters in the brain has a profound application for the understanding of brain disorders. Significant progress in the MR scanner as well as MR pulse sequence development to detect in vivo neurochemicals has been accomplished. The processing of MR signal from these low abundant neurochemicals/neurotransmitters should be very robust and sensitive in order to provide distinctive observations of disease-related neurochemical alterations and their absolute quantitation to aid in early clinical diagnosis. We highlight the diversity in currently available MRS processing tools, and recently introduced, KALPANA, a promising package integrating the end-to-end processing as well as robust quantitation of neurochemicals in a user-friendly approach through a graphical user interface. This further necessitates the futuristic need for advanced MRS processing pipeline and the respective readout can help in early diagnosis and prognosis of diseases in the clinical environment.

[1]  W R Markesbery,et al.  Oxidative stress hypothesis in Alzheimer's disease. , 1997, Free radical biology & medicine.

[2]  P. Mandal,et al.  A Multi-Center Study on Human Brain Glutathione Conformation using Magnetic Resonance Spectroscopy , 2018, Journal of Alzheimer's disease : JAD.

[3]  L O Hall,et al.  Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging , 2006, NMR in biomedicine.

[4]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[5]  Manjari Tripathi,et al.  Brain oxidative stress: detection and mapping of anti-oxidant marker 'Glutathione' in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. , 2012, Biochemical and biophysical research communications.

[6]  Manjari Tripathi,et al.  Brain Glutathione Levels – A Novel Biomarker for Mild Cognitive Impairment and Alzheimer’s Disease , 2015, Biological Psychiatry.

[7]  B. King,et al.  Autism spectrum disorders: Update of evaluation and treatment , 2001, Current psychiatry reports.

[8]  B. Ross,et al.  Clinical NOE 13C MRS for neuropsychiatric disorders of the frontal lobe. , 2008, Journal of magnetic resonance.

[9]  Pravat K Mandal,et al.  In vivo proton magnetic resonance spectroscopic signal processing for the absolute quantitation of brain metabolites. , 2012, European journal of radiology.

[10]  C. Vaidya,et al.  Neurodevelopmental abnormalities in ADHD. , 2012, Current topics in behavioral neurosciences.

[11]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[12]  A. Kersting,et al.  Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study , 2005, Schizophrenia Research.

[13]  Manjari Tripathi,et al.  Mapping of hippocampal pH and neurochemicals from in vivo multi-voxel 31P study in healthy normal young male/female, mild cognitive impairment, and Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[14]  R. Gruetter,et al.  Quantification of vitamin C in the rat brain in vivo using short echo‐time 1H MRS , 2006, Magnetic resonance in medicine.

[15]  P Boesiger,et al.  Detection of glutathione in the human brain in vivo by means of double quantum coherence filtering , 1999, Magnetic resonance in medicine.

[16]  R. Edden,et al.  GABA quantitation using MEGA‐PRESS: Regional and hemispheric differences , 2016, Journal of magnetic resonance imaging : JMRI.

[17]  Varan Govind,et al.  Glutathione Conformations and Its Implications for in vivo Magnetic Resonance Spectroscopy , 2017, Journal of Alzheimer's disease : JAD.

[18]  Theodoros N. Arvanitis,et al.  A constrained least‐squares approach to the automated quantitation of in vivo 1H magnetic resonance spectroscopy data , 2011, Magnetic resonance in medicine.

[19]  P. Mandal,et al.  Quantitation of in vivo brain glutathione conformers in cingulate cortex among age‐matched control, MCI, and AD patients using MEGA‐PRESS , 2019, Human brain mapping.

[20]  B J Soher,et al.  Automated spectral analysis II: Application of wavelet shrinkage for characterization of non‐parameterized signals , 1998, Magnetic resonance in medicine.

[21]  Y. Bozzi,et al.  Epilepsy as a Neurodevelopmental Disorder , 2012, Front. Psychiatry.

[22]  Piero Antuono,et al.  Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors , 2008, The Lancet Neurology.

[23]  R G Shulman,et al.  Cerebral intracellular pH by 31P nuclear magnetic resonance spectroscopy , 1985, Neurology.

[24]  J. Pettegrew,et al.  Brain Membrane Phospholipid Alterations in Alzheimer's Disease , 2001, Neurochemical Research.

[25]  Pravat K. Mandal,et al.  Magnetic Resonance Spectroscopy (MRS) and Its Application in Alzheimer's Disease , 2007 .

[26]  R. de Beer,et al.  Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals , 2001, Comput. Biol. Medicine.

[27]  R. Edden,et al.  Gannet: A batch‐processing tool for the quantitative analysis of gamma‐aminobutyric acid–edited MR spectroscopy spectra , 2014, Journal of magnetic resonance imaging : JMRI.